Mimpara (Cinacalcet)

Cinacalcet, the active ingredient in Mimpara, is a calcimimetic presented as an oral formulation for oral use. It is employed to manage secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and to treat hypercalcemia associated with parathyroid carcinoma.

GNH USA supplies Mimpara as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide, ensuring reliable quality and regulatory compliance.

Mimpara (cinacalcet) acts on the calcium‑sensing pathway to control parathyroid hormone activity.

- Secondary hyperparathyroidism in dialysis patients: reduces parathyroid hormone secretion, helping to lower serum calcium and phosphate levels. - Hypercalcemia due to parathyroid carcinoma: decreases serum calcium concentrations, providing symptomatic relief.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional episodes. - Diarrhea: loose stools. - Hypocalcemia: low blood calcium levels causing tingling. - Muscle cramps: involuntary tightening of muscles. - Headache: mild to moderate pain.

Serious or Rare Side Effects: - Severe hypocalcemia: may lead to seizures or cardiac arrhythmias. - Arrhythmias: irregular heart rhythms. - Seizures: convulsive episodes. - Allergic reactions: rash, itching, swelling. - Pancreatitis: inflammation of the pancreas. - Liver enzyme elevation: abnormal liver function tests.

Mimpara requires careful monitoring and patient education before use. - Monitor calcium levels: check serum calcium regularly to avoid hypocalcemia. - Assess PTH: periodic measurement of parathyroid hormone is recommended. - Adjust dose in renal impairment: consider renal function when dosing. - Caution in pregnancy: safety not established; use only if benefit outweighs risk. - Avoid in severe hypocalcemia: do not initiate therapy when calcium is critically low. - Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Cinacalcet may interact with several medications that affect its metabolism or calcium balance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase cinacalcet exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Calcium supplements taken in high doses: can blunt the drug’s effect on serum calcium.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may modestly raise cinacalcet levels. - Vitamin D analogs (e.g., calcitriol): may require dose adjustment to maintain calcium balance. - Loop diuretics: can enhance calcium loss, necessitating closer monitoring.